Evaluation of biochemical parameter in polycystic ovarian disease patients attending tertiary care hospital

Aditi Saha, Anirban Das Gupta


Background: PCOS might be a complex multigenic disorder with strong epigenetic and environmental influences, such as diet and other lifestyle factors. It is associated with abdominal adiposity, insulin resistance, obesity, metabolic disorders and cardiovascular risk factors. Based on literature search and non-uniformity in the finding of various author present study has been designed to evaluate the biochemical parameter in polycystic ovarian disease patients attending tertiary care hospital.

Methods: The study population include 50 untreated patients diagnosed to be polycystic ovarian disease. Parameters like age, BMI (body mass index), fasting plasma glucose, lipid profile overnight fasting plasma insulin, dehydroepiandrosterne sulphate, (µg/dl) (DHEAS), LH, FSH, LH/FSH ratio, HOMA IR (homeostasis model assessment of insulin resistance) and quantitative insulin sensitivity check index (QUICKI) and fasting serum plasma glucose to insulin ratio was measured in both group of patients.

Results: The mean value of glucose insulin ratio was 4.88±1.911 in PCOD group and 8.74±4.61 in control group, the p value was 0.004909. The mean of LH/FSH ratio was 1.93±0.42 in PCOD group and 1.03±0.199 in control group. The p value was <0.05. The mean of HOMA IR was 7.87±0.87 in PCOD group and 2.036±0.26 in control group, with p value 0.00001.

Conclusions: From present study we can conclude that the mean age was 22.05±4.649 years and the mean BMI was 27.32±6. Hyperglycemia and dyslipidemia were common in PCOD patients. The mean of HOMA IR was significantly higher and the mean value of QUICKI was significantly lower in PCOD group.



Full Text:



Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935;29:181-91.

Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14(5):270-84.

Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016;37(5):467-520.

Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19-25.

Najem F, Elmehdawi R, Swalem A. Clinical and biochemical characteristics of polycystic ovary syndrome in Benghazi- Libya; a retrospective study. Libyan J Med. 2008;3(2):71-4.

Swetha N, Vyshnavi R, Modagan P, Rajagopalan B. A correlative study of biochemical parameters in polycystic ovarian syndrome. Int J Biol Med Res. 2013;4(2):3148-54.

Chae SJ, Kim JJ, Choi YM, Hwang KR, Jee BC, Ku SY, et al. Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women. Hum Reprod. 2008;23(8):1924-31.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9.

Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Su. Quantitative insulin sensitivity check index: a Sullivan Gple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85(7):2402-10.

Ramanand SJ, Ghongane BB, Ramanand JB, Patwardhan MH, Ghanghas RR, Jain SS. Clinical characteristics of polycystic ovary syndrome in Indian women. Indian J Endocrinol Metab. 2013;17(1):138-45.

Wang F, Dai W, Yang XH, Guo YH, Sun YP. Analyses of optimal body mass index for infertile patients with either polycystic or non-polycystic ovary syndrome during assisted reproductive treatment in China. Scient Rep. 2016;6(1):1-9.

Beydoun HA, Stadtmauer L, Beydoun MA, Russell H, Zhao Y, Oehninger S. Polycystic ovary syndrome, body mass index and outcomes of assisted reproductive technologies. Reprod Biomed Online. 2009;18(6):856-63.

Bentley-Lewis R, Seely E, Dunaif A. Ovarian hypertension: polycystic ovary syndrome. Endocrinol Metab Clin North Am. 2011;40(2):433-49,ix-x.

Kiranmayee D, Kavya K, Himabindu Y, Sriharibabu M, Madhuri GLJ, Venu S. Correlations between anthropometry and lipid profile in women with PCOS. J Hum Reprod Sci. 2017;10(3):167-72.

Kheirollahi A, Teimouri M, Karimi M, Vatannejad A, Moradi N, Borumandnia N, et al. Evaluation of lipid ratios and triglyceride-glucose index as risk markers of insulin resistance in Iranian polycystic ovary syndrome women. Lipids Health Dis. 2020;19(1):1-9.

Nahar K, Mahfuza G, Begum SA, Khatun K, Islam MR. Clinical, biochemical and hormonal profile of polycystic ovary syndrome. J Nat Inst Neurosci Bangladesh. 2017;3(2):94-8.

Tosi F, Bonora E, Moghetti P. Insulin resistance in a large cohort of women with polycystic ovary syndrome: a comparison between euglycaemic-hyperinsulinaemic clamp and surrogate indexes. Hum Reprod. 2017;32(12):2515-21.

Goodarzi MO, Carmina E, Azziz R. DHEA, DHEAS and PCOS. J Steroid Biochem Mol Biol. 2015;145:213-25.

Moran C, Arriaga M, Arechavaleta-Velasco F, Moran S. Adrenal androgen excess and body mass index in polycystic ovary syndrome. J Clin Endocrinol Metab. 2015;100(3):942-50.

Smitha M, Jyothi S, Acharya A. A prospective study of insulin resistance among infertile women with polycystic ovarian syndrome. Int J Reprod Contracept Obstet Gynecol. 2018;7:3786-9.